Our mission is to meet the urgent need to develop safe and more potent anti-infectives that are not affected by multidrug resistance mechanisms. We strive to restore anti-infective potency against drug-resistant bacteria and make sustainable improvements in patient care.
To get there, we are improving existing drug classes and discovering new ones to use in combination with known anti-infectives. Leveraging a multi-faceted approach and a deep understanding of drug resistance mechanisms, we are creating novel development strategies and assets that we hope will help overcome multidrug resistance.
We Are Committed
To meet this challenge, innovative approaches are critical, along with continued investment at every stage of drug development. Treatment solutions for specific problems in AMR will rarely occur through a single innovation; we need a broad knowledge base to address areas of high unmet need.
To support our innovation goals, we are expanding our existing R&D capabilities with new state-of-the-art laboratories in San Diego, California that will work in tandem with Shionogiโs research laboratories in Japan. Our scientists explore the mechanisms of AMR to discover new treatments and collaborate with academic, government and clinical scientists. The labs will also train researchers and leaders in the discovery of new treatments for infectious diseases. All of this is with the goal of helping develop the next generation of scientists who will be indispensable in the fight to prevent future pandemics.
In addition, expanding our presence in the U.S. will also provide an opportunity to further develop our partnership network with researchers in the U.S. government, industry and non-profit sectors.